CNSintel offers confidential neuroscientific advice to drug development companies from a global network of prominent neuroscientists.

Our fast and affordable services enable a confidential exchange and review of ideas in neuroscience drug discovery.

Developing CNS drugs is a slow and costly process, and annual reports from the FDA and the EMA reveal that emerging CNS drugs get some of the lowest approval rates. Therefore, independent review of the scientific results at the pre-clinical stage of drug development by a multidisciplinary group of independent experts may be extremely valuable.